GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)
Phase 2
Completed
- Conditions
- Rhinitis, Allergic, Perennial and Seasonal
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 71
- Registration Number
- NCT01957202
- Locations
- 🇦🇹
GSK Investigational Site, Vienna, Austria
A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT01954043
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
Phase 3
Completed
- Conditions
- Herpes Zoster
- Interventions
- Biological: Herpes Zoster vaccine GSK 1437173ABiological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 829
- Registration Number
- NCT01954251
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184
Phase 1
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: GSK2586184 standard formulationDrug: GSK2586184 new formulation
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 37
- Registration Number
- NCT01953835
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women
Phase 1
Withdrawn
- Conditions
- Infections, Bacterial
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2015-01-28
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01953809
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
Not Applicable
Completed
- Conditions
- Malaria
- Interventions
- Procedure: Capillary blood sampleOther: Data collection
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2421
- Registration Number
- NCT01954264
- Locations
- 🇸🇳
GSK Investigational Site, Dakar, Senegal
Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom
Completed
- Conditions
- Infections, Papillomavirus
- Interventions
- Other: Data collection
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2016-12-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1053
- Registration Number
- NCT01953822
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: Investigational H7N1 vaccine GSK2789869ABiological: Placebo
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 363
- Registration Number
- NCT01949090
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis
Phase 2
Completed
- Conditions
- Rhinitis, Allergic, Perennial and Seasonal
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 78
- Registration Number
- NCT01949051
- Locations
- 🇨🇦
GSK Investigational Site, Mississauga, Ontario, Canada
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 111
- Registration Number
- NCT01943851
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom